DK3877395T3 - Industriel fremgangsmåde til fremstilling af estetrol af høj renhed - Google Patents

Industriel fremgangsmåde til fremstilling af estetrol af høj renhed Download PDF

Info

Publication number
DK3877395T3
DK3877395T3 DK20768398.8T DK20768398T DK3877395T3 DK 3877395 T3 DK3877395 T3 DK 3877395T3 DK 20768398 T DK20768398 T DK 20768398T DK 3877395 T3 DK3877395 T3 DK 3877395T3
Authority
DK
Denmark
Prior art keywords
estetrol
production
high purity
industrial process
industrial
Prior art date
Application number
DK20768398.8T
Other languages
English (en)
Inventor
Róbert Lovas
Sándor Mahó
Ildikó Bacsa
Beatrix Mayer
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Application granted granted Critical
Publication of DK3877395T3 publication Critical patent/DK3877395T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20768398.8T 2019-09-03 2020-09-02 Industriel fremgangsmåde til fremstilling af estetrol af høj renhed DK3877395T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1900315A HU231240B1 (hu) 2019-09-03 2019-09-03 Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
PCT/IB2020/058148 WO2021044302A1 (en) 2019-09-03 2020-09-02 Industrial process for the preparation of high purity estetrol

Publications (1)

Publication Number Publication Date
DK3877395T3 true DK3877395T3 (da) 2023-03-06

Family

ID=89992977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20768398.8T DK3877395T3 (da) 2019-09-03 2020-09-02 Industriel fremgangsmåde til fremstilling af estetrol af høj renhed

Country Status (32)

Country Link
US (1) US11633406B2 (da)
EP (1) EP3877395B1 (da)
JP (1) JP7265087B2 (da)
KR (1) KR102871606B1 (da)
CN (1) CN114302889B (da)
AU (1) AU2020343497B2 (da)
CA (1) CA3147815C (da)
CL (1) CL2022000492A1 (da)
CO (1) CO2022003769A2 (da)
CU (1) CU24692B1 (da)
DK (1) DK3877395T3 (da)
EC (1) ECSP22022403A (da)
ES (1) ES2855923T3 (da)
FI (1) FI3877395T3 (da)
GE (1) GEP20247626B (da)
HR (1) HRP20230230T1 (da)
HU (2) HU231240B1 (da)
IL (1) IL290973B2 (da)
JO (1) JOP20220041A1 (da)
LT (1) LT3877395T (da)
MA (1) MA54200B1 (da)
MD (1) MD3877395T2 (da)
MX (1) MX2022002603A (da)
MY (1) MY206905A (da)
PE (1) PE20221418A1 (da)
PH (1) PH12022550388A1 (da)
PL (1) PL3877395T3 (da)
PT (1) PT3877395T (da)
RS (1) RS63966B1 (da)
SI (1) SI3877395T1 (da)
WO (1) WO2021044302A1 (da)
ZA (1) ZA202203557B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112020004564T5 (de) * 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS
HU231651B1 (hu) * 2021-10-01 2025-05-28 Industriale Chimica S.R.L. Eljárás (15alfa,16alfa,17béta)-ösztra-1,3,5(10)-trién-3,15,16,17-tetrol (esztetrol) és esztetrol-monohidrát előállítására
JP2026503158A (ja) * 2023-02-02 2026-01-27 インダストリアーレ キミカ エッセ.エッレ.エッレ. (15α,16α,17β)-エストラ-1,3,5(10)-トリエン-3,15,16,17-テトロール(エステトロール)一水和物の調製方法
CN117088928B (zh) * 2023-08-16 2025-09-09 湖北共同甾体药物研究院有限公司 用于制备高纯度雌四醇的工艺
CN119569803B (zh) * 2023-09-05 2025-09-16 秦皇岛紫竹药业有限公司 一种制备高纯度雌四醇的方法
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás
CN119112905B (zh) * 2024-09-10 2026-07-28 武汉九珑人福药业有限责任公司 含雌孕激素的药物组合物、药物制剂及其制备方法、应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE60234515D1 (de) 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DE60216630T2 (de) 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
SI1511496T1 (sl) 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2004037269A1 (en) 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
CN100343269C (zh) * 2002-11-08 2007-10-17 潘塔希生物科学股份有限公司 通过雌酮衍生的甾体化合物合成雌四醇
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CA2843951C (en) 2011-08-11 2019-08-06 Wout WOUTERS Use of estetrol as emergency contraceptive
AU2012320423C1 (en) * 2011-10-07 2018-01-25 Estetra Srl Process for the production of estetrol
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2013034780A2 (en) * 2012-12-20 2013-03-14 Crystal Pharma, S.A.U. Process for the preparation of estetrol and related compounds
ES2624667T3 (es) * 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
DK3079671T3 (da) 2013-12-12 2017-12-11 Donesta Bioscience B V Oralt disintegrerende fast doseringsenhed indeholdende en estetrol-komponent
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
SG11202000881VA (en) 2017-08-01 2020-02-27 Fund Sa Adjuvant therapy for use in prostate cancer treatment
IL276584B2 (en) 2018-02-07 2024-10-01 Estetra Srl Contraceptive composition with reduced cardiovascular effects
DE112020004564T5 (de) 2019-09-27 2022-06-15 Industriale Chimica S.R.L. VERFAHREN ZUM HERSTELLEN VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIEN-3,15,16,17-TETROL (ESTETROL) UND ZWISCHENSTUFEN DES VERFAHRENS

Also Published As

Publication number Publication date
FI3877395T3 (fi) 2023-03-18
MY206905A (en) 2025-01-15
ES2855923T3 (es) 2023-04-28
GEP20247626B (en) 2024-05-27
RS63966B1 (sr) 2023-03-31
CO2022003769A2 (es) 2022-04-19
MD3877395T2 (ro) 2023-05-31
JP7265087B2 (ja) 2023-04-25
PT3877395T (pt) 2023-02-02
WO2021044302A1 (en) 2021-03-11
HU231240B1 (hu) 2022-04-28
SI3877395T1 (sl) 2023-03-31
HRP20230230T1 (hr) 2023-04-14
EP3877395B1 (en) 2022-12-07
BR112022003254A2 (pt) 2022-05-17
EP3877395A1 (en) 2021-09-15
CU24692B1 (es) 2024-01-10
HUE061427T2 (hu) 2023-07-28
KR102871606B1 (ko) 2025-10-16
CN114302889A (zh) 2022-04-08
CL2022000492A1 (es) 2023-03-10
MX2022002603A (es) 2022-03-25
ZA202203557B (en) 2022-11-30
PE20221418A1 (es) 2022-09-20
MA54200A (fr) 2022-04-27
PH12022550388A1 (en) 2024-01-29
NZ786568A (en) 2026-01-30
AU2020343497B2 (en) 2023-02-02
LT3877395T (lt) 2023-02-27
AU2020343497A1 (en) 2022-04-14
US11633406B2 (en) 2023-04-25
KR20220071206A (ko) 2022-05-31
US20220296609A1 (en) 2022-09-22
ECSP22022403A (es) 2022-04-29
IL290973B1 (en) 2023-07-01
JP2022546016A (ja) 2022-11-02
PL3877395T3 (pl) 2023-05-08
MA54200B1 (fr) 2023-02-28
CN114302889B (zh) 2023-08-29
HUP1900315A1 (hu) 2021-03-29
JOP20220041A1 (ar) 2023-01-30
ES2855923T1 (es) 2021-09-24
CA3147815A1 (en) 2021-03-11
CA3147815C (en) 2023-03-28
IL290973B2 (en) 2023-11-01
IL290973A (en) 2022-05-01
CU20220013A7 (es) 2022-10-11

Similar Documents

Publication Publication Date Title
DK4107252T3 (da) Fremgangsmåde til fremstillingen af aav
DK3874053T3 (da) Fremgangsmåde til anvendelse af industriel co2-holdig gas til fremstilling af en methanberiget gassammensætning
MA49689A (fr) Procédé de production de cannabinoïdes à partir de types de chanvre industriel
DK3312270T3 (da) Fremgangsmåde til fremstilling af plader med høj ydeevne
PL3877395T3 (pl) Przemysłowy sposób otrzymywania estetrolu o wysokiej czystości
DK3766570T3 (da) Fremgangsmåde til fremstilling af alkoxylater
DK3880641T3 (da) Fremgangsmåde til fremstilling af glycerider af hydroxycarboxylsyrer
DK3481811T3 (da) Industriel fremgangsmåde til forberedelse af cariprazin
DK3464305T3 (da) Fremgangsmåder til fremstilling af oligomerer
EP3891114A4 (en) PROCESS FOR THE PRODUCTION OF HIGH PURITY TRIFLUORIODOMETHANE
HUE062801T2 (hu) Javított eljárás nagytisztaságú ólom elõállítására
EP3872096A4 (en) PROCESS FOR THE SECRETORY PRODUCTION OF A PROTEIN
DK3749668T3 (da) Kontinuerlig fremgangsmåde til fremstilling af trazodonbase
SG11202101575TA (en) Process for the production of high purity isobutylene
DK3592723T3 (da) Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en
EP4083012C0 (en) PROCESS FOR THE PRODUCTION OF BIS(AMINOMETHYL)CYCLOHEXANE
EP3831804A4 (en) PROCESS FOR THE PREPARATION OF 1-ACYLOXY-2-METHYL-2-PROPEN
EP3847675C0 (en) Process for the production of gallium radionuclides
DK3305754T3 (da) Fremgangsmåder til fremstilling af højumættet fedtsyre med høj renhed med højt udbytte
DK4097117T3 (da) Fremgangsmåde til fremstilling af nukleinsyreoligomer
DK3620452T3 (da) Fremgangsmåde til fremstilling af lenvatinib
DK3362433T3 (da) Industriel fremgangsmåde til fremstilling af (5s,10s)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (e)-3-carboxyacrylat-salt
HUE064895T2 (hu) Eljárás palbociklib elõállítására
DK3880649T3 (da) Fremgangsmåde til fremstilling af polyolbaserede estere af hydroxycarboxylsyrer
DK3864016T3 (da) Fremgangsmåde til fremstilling af substituerede imidazolderivater